---
input_text: 'Sickle Cell Disease: A Review. Importance: Sickle cell disease (SCD)
  is an inherited disorder of hemoglobin, characterized by formation of long chains
  of hemoglobin when deoxygenated within capillary beds, resulting in sickle-shaped
  red blood cells, progressive multiorgan damage, and increased mortality. An estimated
  300 000 infants are born annually worldwide with SCD. Most individuals with SCD
  live in sub-Saharan Africa, India, the Mediterranean, and Middle East; approximately
  100 000 individuals with SCD live in the US. Observations: SCD is diagnosed through
  newborn screening programs, where available, or when patients present with unexplained
  severe atraumatic pain or normocytic anemia. In SCD, sickling and hemolysis of red
  blood cells result in vaso-occlusion with associated ischemia. SCD is characterized
  by repeated episodes of severe acute pain and acute chest syndrome, and by other
  complications including stroke, chronic pain, nephropathy, retinopathy, avascular
  necrosis, priapism, and leg ulcers. In the US, nearly all children with SCD survive
  to adulthood, but average life expectancy remains 20 years less than the general
  population, with higher mortality as individuals transition from pediatric to adult-focused
  health care systems. Until 2017, hydroxyurea, which increases fetal hemoglobin and
  reduces red blood cell sickling, was the only disease-modifying therapy available
  for SCD and remains first-line therapy for most individuals with SCD. Three additional
  therapies, L-glutamine, crizanlizumab, and voxelotor, have been approved as adjunctive
  or second-line agents. In clinical trials, L-glutamine reduced hospitalization rates
  by 33% and mean length of stay from 11 to 7 days compared with placebo. Crizanlizumab
  reduced pain crises from 2.98 to 1.63 per year compared with placebo. Voxelotor
  increased hemoglobin by at least 1 g/dL, significantly more than placebo (51% vs
  7%). Hematopoietic stem cell transplant is the only curative therapy, but it is
  limited by donor availability, with best results seen in children with a matched
  sibling donor. While SCD is characterized by acute and chronic pain, patients are
  not more likely to develop addiction to pain medications than the general population.
  Conclusions and Relevance: In the US, approximately 100 000 people have SCD, which
  is characterized by hemolytic anemia, acute and chronic pain, acute chest syndrome;
  increased incidence of stroke, nephropathy, and retinopathy; and a life span that
  is 20 years shorter than the general population. While hydroxyurea is first-line
  therapy for SCD, L-glutamine, crizanlizumab, and voxelotor have been approved in
  the US since 2017 as adjunctive or second-line treatments, and hematopoietic stem
  cell transplant with a matched sibling donor is now standard care for severe disease.'
raw_completion_output: |-
  primary_disease: Sickle Cell Disease (SCD)
  medical_actions: Newborn screening programs; Hydroxyurea; L-glutamine; Crizanlizumab; Voxelotor; Hematopoietic stem cell transplant
  symptoms: Severe atraumatic pain; Normocytic anemia; Vaso-occlusion; Ischemia; Severe acute pain; Acute chest syndrome; Stroke; Chronic pain; Nephropathy; Retinopathy; Avascular necrosis; Priapism; Leg ulcers
  chemicals: Hydroxyurea; L-glutamine; Crizanlizumab; Voxelotor
  action_annotation_relationships: Newborn screening programs PREVENTS Severe atraumatic pain IN Sickle Cell Disease (SCD); Newborn screening programs PREVENTS Normocytic anemia IN Sickle Cell Disease (SCD); Hydroxyurea TREATS Severe acute pain IN Sickle Cell Disease (SCD); Hydroxyurea TREATS Acute chest syndrome IN Sickle Cell Disease (SCD); Hydroxyurea (with Hydroxyurea) TREATS Stroke IN Sickle Cell Disease (SCD); L-glutamine (with L-glutamine) TREATS Severe acute pain IN Sickle Cell Disease (SCD); Crizanlizumab (with Crizanlizumab) TREATS Severe acute pain IN Sickle Cell Disease (SCD); Voxelotor (with Voxelotor) TREATS Normocytic anemia IN Sickle Cell Disease (SCD); Hematopoietic stem cell transplant TREATS Sickle Cell Disease (SCD)
prompt: |+
  From the text below, extract the following entities in the following format:

  subject_extension: <A chemical or drug mentioned in the relationship between the medical action and the symptom, for example, "analgesic agent therapy" has the aspect "analgesic">
  object_extension: <An optional term describing some specific aspect of the object, e.g. "analgesic agent therapy" has the aspect "analgesic">
  subject: <The medical action. For example: blood transfusion, radiation therapy, cardiac catheterization, pulse oximetry, otoscopy>
  predicate: <The relationship type between the medical action and the symptom, usually TREATS or PREVENTS.>
  object: <A sign or symptom associated with the disease and targeted by the medical action. For example, Low serum calcitriol, hypoplasia of the thymus, chronic cough, aortic stiffness, low pulse pressure>
  qualifier: <The primary disease the relationship is about, or specifically the disease the symptom is related to. For example, Beck-Fahrner syndrome, hereditary retinoblastoma, progeria, diabetes mellitus, infectious otitis media>
  subject_qualifier: <An optional qualifier or modifier for the subject of the statement, e.g. "high dose" or "intravenously administered">
  object_qualifier: <An optional qualifier or modifier for the object of the statement, e.g. "severe" or "with additional complications">


  Text:
  Hematopoietic stem cell transplant TREATS Sickle Cell Disease (SCD)

  ===

extracted_object:
  primary_disease: MONDO:0007374
  medical_actions:
    - Newborn screening programs
    - Hydroxyurea
    - L-glutamine
    - Crizanlizumab
    - Voxelotor
    - Hematopoietic stem cell transplant
  symptoms:
    - Severe atraumatic pain
    - HP:0001897
    - Vaso-occlusion
    - Ischemia
    - Severe acute pain
    - Acute chest syndrome
    - HP:0001297
    - HP:0012532
    - HP:0000112
    - HP:0000488
    - HP:0010885
    - HP:0200023
    - Leg ulcers
  chemicals:
    - CHEBI:44423
    - CHEBI:18050
    - Crizanlizumab
    - Voxelotor
  action_annotation_relationships:
    - subject: <Newborn screening programs>
      predicate: <PREVENTS>
      object: <Severe atraumatic pain>
      qualifier: MONDO:0007374
      subject_qualifier: <None>
      object_qualifier: <None>
      subject_extension: <None>
      object_extension: <None>
    - subject: <Newborn screening programs>
      predicate: <PREVENTS>
      object: <Normocytic anemia>
      qualifier: MONDO:0007374
      subject_qualifier: <None>
      object_qualifier: <None>
      subject_extension: <None>
      object_extension: <None>
    - subject: Hydroxyurea
      predicate: TREATS
      object: Severe acute pain
      qualifier: MONDO:0007374
      object_qualifier: Severe
      subject_extension: CHEBI:44423
    - subject: Hydroxyurea
      predicate: TREATS
      object: Acute chest syndrome
      qualifier: MONDO:0007374
      subject_extension: CHEBI:44423
    - subject: Hydroxyurea
      predicate: TREATS
      object: HP:0001297
      qualifier: MONDO:0007374
      subject_qualifier: with Hydroxyurea
      subject_extension: CHEBI:44423
    - subject: L-glutamine
      predicate: TREATS
      object: Severe acute pain
      qualifier: MONDO:0007374
      subject_qualifier: with L-glutamine
      object_qualifier: Severe
      subject_extension: CHEBI:18050
    - subject: Crizanlizumab
      predicate: TREATS
      object: Severe acute pain
      qualifier: MONDO:0007374
      subject_qualifier: with Crizanlizumab
      object_qualifier: Severe
      subject_extension: Crizanlizumab
    - subject: Voxelotor
      predicate: TREATS
      object: HP:0001897
      qualifier: MONDO:0007374
      subject_qualifier: with Voxelotor
      subject_extension: Voxelotor
    - subject: Hematopoietic stem cell transplant
      predicate: TREATS
      object: HP:0007760
named_entities:
  - id: MONDO:0007374
    label: Sickle Cell Disease (SCD)
  - id: MAXO:0000747
    label: Allogeneic hematopoietic stem cell transplantation (HSCT)
  - id: HP:0007760
    label: Sickle Cell Disease (SCD)
  - id: MAXO:0001001
    label: Gene therapy
  - id: CHEBI:28901
    label: Busulfan
  - id: MONDO:0020380
    label: Sickle cell anemia (SCA)
  - id: HP:0001297
    label: Stroke
  - id: CHEBI:44423
    label: Hydroxyurea
  - id: MONDO:0011382
    label: sickle cell anemia
  - id: MAXO:0000149
    label: allogeneic human leukocyte antigen (HLA)-matched sibling and haploidentical
      hematopoietic cell transplant (HCT)
  - id: CHEBI:17303
    label: morphine
  - id: CHEBI:35482
    label: opioid analgesics
  - id: HP:0012532
    label: chronic pain
  - id: CHEBI:6121
    label: ketamine
  - id: HP:0012531
    label: pain
  - id: MAXO:0000748
    label: fecal microbiota transplantation (FMB)
  - id: CHEBI:26666
    label: SCFA
  - id: CHEBI:17968
    label: butyrate
  - id: CHEBI:31011
    label: valerate
  - id: CHEBI:17272
    label: propionate
  - id: MONDO:0005399
    label: Venous thromboembolism (VTE)
  - id: HP:0002140
    label: Ischemic cerebrovascular accidents
  - id: HP:0002098
    label: respiratory distress
  - id: CHEBI:8735
    label: PAINReportIt(R)
  - id: MAXO:0000066
    label: Oxygen supplementation
  - id: MAXO:0000756
    label: Blood transfusions
  - id: HP:0002094
    label: Dyspnea
  - id: CHEBI:33281
    label: antibiotic
  - id: MAXO:0001175
    label: Liver transplantation
  - id: HP:0001395
    label: Liver fibrosis
  - id: MAXO:0000750
    label: conditioning regimen (alemtuzumab, total body irradiation, and sirolimus
      for GVHD prophylaxis)
  - id: CHEBI:9168
    label: sirolimus
  - id: MONDO:0005812
    label: Influenza
  - id: MONDO:0100096
    label: COVID-19
  - id: MONDO:0003847
    label: Genetic diseases
  - id: MONDO:0002492
    label: Acute Kidney Injury (AKI)
  - id: CHEBI:35457
    label: angiotensin-converting enzyme inhibitors
  - id: HP:0001919
    label: AKI
  - id: MONDO:0005300
    label: chronic kidney disease
  - id: HP:0031589
    label: Suicidal ideation
  - id: HP:0000739
    label: anxiety
  - id: MONDO:0005252
    label: heart failure
  - id: MONDO:0005249
    label: pneumonia
  - id: MONDO:0005068
    label: MI
  - id: MONDO:0011751
    label: COPD
  - id: HP:0001907
    label: Thromboembolic events
  - id: HP:0100602
    label: Preeclampsia
  - id: HP:0001511
    label: Fetal growth restriction
  - id: HP:0001622
    label: Preterm birth
  - id: HP:0003826
    label: Stillbirth
  - id: MAXO:0001479
    label: allogeneic hematopoietic stem cell transplantation
  - id: CHEBI:18050
    label: l-glutamine
  - id: HP:0008209
    label: Premature ovarian insufficiency
  - id: HP:0004870
    label: Chronic hemolytic anemia
  - id: CHEBI:17115
    label: Statistical Software Package(s)
  - id: HP:0001903
    label: anemia
  - id: MAXO:0000503
    label: Mechanical ventilation
  - id: MONDO:0010094
    label: sickle cell trait (SCT)
  - id: HP:0000822
    label: hypertension
  - id: HP:0001626
    label: cardiovascular disease
  - id: HP:0000093
    label: proteinuria
  - id: HP:0000083
    label: kidney failure
  - id: HP:0000112
    label: kidney disease
  - id: HP:0001997
    label: Gout
  - id: HP:0002863
    label: myelodysplastic syndrome
  - id: HP:0003418
    label: Back pain
  - id: HP:0002018
    label: Nausea
  - id: HP:0002019
    label: Constipation
  - id: HP:0002014
    label: Diarrhea
  - id: HP:0100785
    label: Insomnia
  - id: CHEBI:50443
    label: hematopoietic stem cells (HSCs)
  - id: HP:0000789
    label: infertility
  - id: CHEBI:41879
    label: dexamethasone
  - id: CHEBI:64360
    label: Tocilizumab
  - id: MONDO:0011549
    label: Hyperhemolysis syndrome (HHS)
  - id: HP:0001896
    label: Reticulocytopenia
  - id: MAXO:0001017
    label: Vaccination
  - id: CHEBI:66919
    label: Ruxolitinib
  - id: CHEBI:76612
    label: Ibrutinib
  - id: MONDO:0013517
    label: beta-thalassemia (beta-TM)
  - id: MONDO:0005047
    label: Infertility
  - id: CHEBI:46195
    label: Acetaminophen
  - id: CHEBI:41423
    label: Celecoxib
  - id: CHEBI:63629
    label: Tizanidine
  - id: CHEBI:6129
    label: Ketorolac
  - id: MONDO:0005290
    label: Rhabdomyolysis
  - id: MAXO:0001121
    label: Kidney biopsy
  - id: MAXO:0000387
    label: Muscle biopsy
  - id: MAXO:0000950
    label: Supportive care
  - id: CHEBI:4027
    label: Cyclophosphamide
  - id: MONDO:0005632
    label: Acute chest syndrome
  - id: CHEBI:16480
    label: nitric oxide
  - id: CHEBI:28304
    label: heparin
  - id: MONDO:0013730
    label: Graft versus host disease (GvHD)
  - id: MAXO:0010030
    label: Bone marrow transplantation
  - id: HP:0002615
    label: Hypotension
  - id: HP:0001662
    label: Bradycardia
  - id: CHEBI:119915
    label: Fentanyl
  - id: MONDO:0006497
    label: Chronic Pancreatitis (CP)
  - id: MAXO:0035049
    label: Endoscopic retrograde cholangiopancreatography
  - id: MAXO:0000004
    label: Surgical procedures
  - id: MAXO:0000088
    label: Dietary interventions
  - id: MONDO:0005003
    label: Chronic Pancreatitis
  - id: CHEBI:17334
    label: penicillin
  - id: HP:0000716
    label: Depression
  - id: MONDO:0001754
    label: Eclampsia
  - id: MONDO:0010088
    label: Musculoskeletal diseases (MSD)
  - id: HP:0034057
    label: congenital defects
  - id: MAXO:0001077
    label: Splenectomy
  - id: HP:0010972
    label: Ineffective erythropoiesis
  - id: MAXO:0000127
    label: genetic testing
  - id: MONDO:0044348
    label: Hemoglobinopathies
  - id: HP:0000026
    label: Testicular failure
  - id: CHEBI:143719
    label: Hib
  - id: CHEBI:143712
    label: menC
  - id: HP:0002090
    label: pneumonia
  - id: HP:0000407
    label: sensorineural hearing loss
  - id: CHEBI:8455
    label: Proguanil
  - id: CHEBI:8673
    label: Pyrimethamine
  - id: MAXO:0009101
    label: Early intervention
  - id: MAXO:0000827
    label: serum ferritin (FER) level measurement
  - id: CHEBI:49005
    label: Deferasirox
  - id: MONDO:0003664
    label: Haemolytic anaemia
  - id: HP:0001923
    label: Reticulocytosis
  - id: HP:0025435
    label: Increased lactate dehydrogenase levels
  - id: HP:0011981
    label: Pigment gallstones
  - id: CHEBI:35341
    label: Steroids
  - id: HP:0001878
    label: Haemolytic anaemia
  - id: HP:0001890
    label: autoimmune haemolytic anaemia
  - id: MAXO:0000021
    label: Palliative care (PC)
  - id: MONDO:0000984
    label: Thalassemia
  - id: MONDO:0004992
    label: Cancer
  - id: HP:0002664
    label: Cancer
  - id: MAXO:0000058
    label: Pharmacological treatment
  - id: HP:0001897
    label: Normocytic anemia
  - id: HP:0000488
    label: Retinopathy
  - id: HP:0010885
    label: Avascular necrosis
  - id: HP:0200023
    label: Priapism
